Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a ...

Medically reviewed by Matthew Wosnitzer, MD Erectile dysfunction (ED) is an inability to achieve or maintain an erection ...

Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald ...